Redburn Atlantic Upgrades Autolus Therapeutics (NASDAQ:AUTL) to Buy

Redburn Atlantic upgraded shares of Autolus Therapeutics (NASDAQ:AUTL) from a neutral rating to a buy rating in a research report released on Friday morning, Marketbeat.com reports. Redburn Atlantic currently has $13.00 price target on the stock.

Separately, Needham & Company LLC reissued a “buy” rating and issued a $9.00 price target on shares of Autolus Therapeutics in a report on Monday, November 11th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $9.45.

Autolus Therapeutics Trading Up 2.3 %

AUTL stock opened at $3.08 on Friday. Autolus Therapeutics has a 1-year low of $2.94 and a 1-year high of $7.45. The business’s 50 day simple moving average is $3.91 and its 200 day simple moving average is $3.99. The firm has a market capitalization of $819.56 million, a PE ratio of -2.55 and a beta of 2.04.

Autolus Therapeutics (NASDAQ:AUTL) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.10). During the same quarter in the previous year, the business posted ($0.26) EPS. As a group, sell-side analysts predict that Autolus Therapeutics will post -0.94 EPS for the current fiscal year.

Institutional Investors Weigh In On Autolus Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Wellington Management Group LLP increased its position in Autolus Therapeutics by 35.4% during the third quarter. Wellington Management Group LLP now owns 24,220,226 shares of the company’s stock worth $87,919,000 after acquiring an additional 6,330,392 shares during the period. State Street Corp increased its holdings in Autolus Therapeutics by 1.7% in the 3rd quarter. State Street Corp now owns 606,544 shares of the company’s stock worth $2,202,000 after purchasing an additional 10,401 shares in the last quarter. HighVista Strategies LLC raised its stake in shares of Autolus Therapeutics by 2.7% during the third quarter. HighVista Strategies LLC now owns 533,024 shares of the company’s stock valued at $1,935,000 after acquiring an additional 14,204 shares during the last quarter. Erste Asset Management GmbH bought a new position in shares of Autolus Therapeutics during the third quarter worth about $708,000. Finally, Bellevue Group AG lifted its position in shares of Autolus Therapeutics by 27.7% in the 3rd quarter. Bellevue Group AG now owns 41,500 shares of the company’s stock worth $151,000 after purchasing an additional 9,000 shares during the period. Institutional investors and hedge funds own 72.83% of the company’s stock.

Autolus Therapeutics Company Profile

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.